Ocugen, Inc. (OCGN)
Develops gene therapies and vaccines to treat inherited eye diseases and other conditions.
$1.24-0.02%Healthcare
StockGlow Score
Leaning Bearish
BearishBullish
1 year ago+24.7%
The outlook
Ocugen is trading near its 52-week lows with a bearish lean from analysts overall. The stock sits well below both its 50- and 200-day moving averages, signaling downward momentum. However, the average analyst price target sits significantly higher than the current price, reflecting some longer-term optimism despite near-term weakness.
What’s behind the score
Price trendBelow its 50- & 200-day averages
52-week range17% of the way from its 52-week low to high
Price targetAvg target +822% vs current price
Analyst price target
~12-month · 7 analysts$11.43average target+821.7% vs now
Now $1.24
Low $7.00High $22.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$419.8M
52-wk high
$2.73
52-wk low
$0.93
50-day avg
$1.35
200-day avg
$1.53
Trailing P/E
—